129 Cabazitaxel for metastatic castration resistant prostate cancer (mCRPC): Interim safety and quality of life (QOL) data from the UK early access programme

✍ Scribed by A.K. Bahl; S. Masson; Z. Malik; A. Birtle; S. Sundar; R. Jones; N. James; M. Mason; S. Kumar; D. Bottomley; A. Lydon; S. Chowdhury; J. Wylie; J. De Bono

• Book ID: 119624065
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 20 KB
• Volume: 11
• Category: Article
• ISSN: 1569-9056
• DOI: 10.1016/s1569-9056(12)60128-6